PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company's lead candidate for the treatment of Alzheimer's disease, were published in The Journal of Prevention of Alzheimer's Disease. SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Al ...

Financial Data and Key Metrics Changes - As of June 30, 2024, the company reported cash and cash equivalents of approximately $28.5 million and total grant funds remaining from the NIA of $57.3 million, indicating sufficient cash to fund operations into the second quarter of 2025 [18] - The net loss for the second quarter was $7 million or $0.18 per share, compared to a net loss of $4.7 million or $0.16 per share for the same period in 2023 [19] Business Line Data and Key Metrics Changes - Research and development expenses increased to $11.6 million for the second quarter of 2024 from $8.5 million in the same period of 2023, primarily due to higher costs associated with advancing clinical programs [18] - General and administrative expenses decreased to $3.1 million for the second quarter of 2024 from $3.3 million in the same period of 2023, attributed to lower professional services [19] Market Data and Key Metrics Changes - The SHINE trial showed a 39% slowing of cognitive decline in participants treated with CT1812 compared to placebo, indicating a significant potential in the Alzheimer's disease market [6][11] - The SHIMMER trial is expected to report top-line results by year-end, focusing on dementia with Lewy bodies, a market with an estimated 1.5 million affected individuals in the U.S. [13][14] Company Strategy and Development Direction - The company is focused on developing innovative drug candidates targeting age-related degenerative conditions of the CNS and retina, with ongoing Phase 2 trials for Alzheimer's disease and other conditions [4] - Future trials will be larger and longer to better assess the efficacy of CT1812, with a focus on safety and tolerability [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the SHINE trial results, highlighting the consistent trends in cognitive improvement and the favorable safety profile of CT1812 [11][12] - The company plans to engage with leading neurologists to discuss next steps in CT1812 development, indicating a proactive approach to advancing their clinical programs [12] Other Important Information - The company has published multiple manuscripts and made presentations at medical conferences, supporting its development efforts and providing insights into the mechanisms of CT1812 [16] - The START trial is actively recruiting participants with early Alzheimer's disease, allowing for real-world evidence of CT1812's potential as both monotherapy and in combination with other treatments [15] Q&A Session Summary Question: Regarding the SHINE trial, how did the 100 mg dose affect A-beta levels? - The 100 mg dose did not significantly alter A-beta levels, while the 300 mg did, with expectations that longer trials may show more pronounced effects [20][22] Question: How does the company plan to extend its cash runway for later-stage trials? - The company is evaluating various options to extend its cash runway and will consider all available options as it designs the next stage of trials [23] Question: Is there potential synergy between CT1812 and GLP-1 receptor agonists for Alzheimer's treatment? - Management expressed interest in exploring potential synergies, noting that CT1812's mechanism could complement other therapies [24] Question: What are the key learnings from the SHINE trial for future studies? - Key learnings include the consistent trend in cognitive outcomes and the identification of a dose range that shows efficacy without significant adverse events [31][32] Question: How has the recent approval of Alzheimer's drugs affected trial enrollment? - The general awareness and interest in Alzheimer's treatments have positively impacted recruitment, although the patient populations for different trials are somewhat distinct [33]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40886 Cognition Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 13-4365359 ...

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update - Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB by YE 2024 - - Company to Host Investor Conference Call at 8:30 a.m. - Purchase, NY – August 8, 2024 – Cognition The ...

PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the "Company" or "Cognition"), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating ...

Core Viewpoint - Cognition Therapeutics, Inc. is set to release its financial results for Q2 2024 on August 8, 2024, and will host a conference call to discuss these results and provide a business update [1]. Group 1: Financial Results Announcement - The financial results for the second quarter ended June 30, 2024, will be released before the market opens on August 8, 2024 [1]. - A conference call will take place at 8:30 a.m. ET on the same day to review the financial and operating results [1]. Group 2: Conference Call Details - The conference call can be accessed via a toll-free number for US/Canada participants: (800) 715-9871, and an international dial-in number: (646) 307-1963 [2]. - The conference ID number for the call is 3702003 [2]. - An audio webcast with live Q&A will be available, and an archive of the webcast will be accessible for 90 days starting at approximately 10:30 a.m. ET on August 8, 2024 [2]. Group 3: Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina [3]. - The company is investigating its lead candidate CT1812 in clinical programs for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration [3]. - CT1812 targets the σ-2 receptor, representing a distinct mechanism compared to other current treatment approaches for degenerative diseases [3].

Cognition Therapeutics (NASDAQ:CGTX) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 'SHINE' study. On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. More Monday Stock Market News What's Next for CGTX Stock Thi ...

- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration - - Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings - "The SHINE trial showed that after 182 days of treatment, CT1812 demonstrated evidence of clinical improvements ...

Core Insights - Cognition Therapeutics, Inc. reported positive results from the Phase 2 'SHINE' study of CT1812, showing cognitive improvement in participants treated for six months compared to placebo across various cognitive measures [1][9][12] - The study demonstrated a favorable safety and tolerability profile, with most treatment-related adverse events being mild or moderate [10][12][18] - CT1812 showed significant changes in neurofilament light chain, a marker of neurodegeneration, particularly at the 300mg dose [2][12] Study Details - The SHINE study enrolled 153 adults with mild-to-moderate Alzheimer's disease, randomized to receive either placebo or one of two doses of CT1812 (100mg or 300mg) [18][22] - The primary endpoint was safety and tolerability, while the key secondary endpoint focused on cognitive measures, specifically ADAS-Cog 11 [22] - Participants in the placebo arm experienced a decline of approximately 2.70 points on ADAS-Cog 11, while those treated with CT1812 declined by an average of 1.66 points, indicating a 39% slowing of decline [18][22] Clinical Implications - The results suggest that CT1812 may serve as a monotherapy or in combination with approved drugs for treating Alzheimer's disease and related dementias [9][12] - The findings from the SHINE study will inform future clinical trials and dose selection for CT1812 [9][12][12] - The company is also conducting additional studies, including the SHIMMER trial for Lewy body dementia and the START trial for early-stage Alzheimer's disease [11][23] Safety Profile - The overall percentage of participants experiencing any adverse event was similar between CT1812 treatment arms (76.5%) and the placebo group (78%) [10][12] - Serious adverse events were reported in 6% of CT1812-treated participants compared to 10% in the placebo group [19] - Treatment-emergent liver function test (LFT) increases were observed in the 300mg group but subsided after drug cessation without serious liver injury [3][10] Future Outlook - The company is optimistic about the SHINE results and anticipates further insights from ongoing trials [11][12] - Cognition Therapeutics has received over $170 million in grant support from various institutions, aiding its research and development efforts [11] - The company aims to advance CT1812 in clinical trials targeting neurodegenerative diseases, leveraging the distinct mechanism of action of the σ-2 receptor [24]

The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial which enrolled 153 patients with mild-to-moderate Alzheimer's disease. Participants were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. Endpoints include safety, cognitive function as measured by the ADAS-Cog 11, a globally recognized cognitive scale, and biomarker evidence of disease modification. The SHINE study was supported by two grant ...